Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | CDK7 | P50613 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4378912 | 0.86 | HPGDS (0.59) | HPGDSCDK5CA12CA2CA3 | |
| SCHEMBL534707 | 0.84 | MAP4K4 (0.44) | CDK5MAP4K4CDK8CLK2CDK7 | |
| SCHEMBL1894034 | 0.79 | EGFR (0.53) | HPGDSMAP4K4ALDH1A1HTTCDC7 | |
| SCHEMBL3879836 | 0.79 | HPGDS (0.47) | HPGDSMAP4K4LRRK2ALDH1A1HTT | |
| SCHEMBL12850560 | 0.79 | HPGDS (0.47) | HPGDSMAP4K4ALDH1A1HTTCDC7 | |
| SCHEMBL12850742 | 0.79 | HPGDS (0.47) | HPGDSMAP4K4ALDH1A1HTTCDC7 | |
| SCHEMBL15125079 | 0.79 | HPGDS (0.51) | HPGDSALDH1A1 | |
| SCHEMBL17442585 | 0.78 | HPGDS (0.44) | HPGDSCDK8ALDH1A1HTTCDC7 | |
| SCHEMBL535363 | 0.77 | ALDH1A1 (0.41) | CDK5MAP4K4CDK8CLK2CDK7 | |
| SCHEMBL63442 | 0.76 | ALDH1A1 (0.57) | HPGDSCA2ALDH1A1PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113905715-B | Light enhancement processing method | 宝洁公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2012170371-A1 | COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS | N30 PHARMACEUTICALS, LLC (US) | 2012-12-13 | — | — | WO | disclosed |
| US-7371764-B2 | Quinolin-isoquinolin-and quinazolin-oxyalkylamides and their use as fungicides | SYNGENTA LIMITED (GB) | 2008-05-13 | — | — | US | disclosed |
| EP-1567010-B1 | QUINOLIN-, ISOQUINOLIN-, AND QUINAZOLIN-OXYALKYLAMIDES AND THEIR USE AS FUNGICIDES | SYNGENTA LTD (GB) | 2007-10-24 | — | — | EP | disclosed |
| US-20070072884-A1 | QUINOLIN-ISOQUINOLIN-AND QUINAZOLIN-OXYALKYLAMIDES AND THEIR USE AS FUNGICIDES | SYNGENTA LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-7122672-B2 | Quinolin-, isoquinolin-, and quinazolin-oxyalkylamides and their use as fungicides | SYNGENTA LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| US-20060019973-A1 | Quinolin-,isoquinolin-,and quinazolin-oxyalkylamides and their use as fungicides | SYNGENTA LIMITED (GB) | 2006-01-26 | — | — | US | disclosed |
| EP-1567010-A1 | QUINOLIN-, ISOQUINOLIN-, AND QUINAZOLIN-OXYALKYLAMIDES AND THEIR USE AS FUNGICIDES | Syngenta Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004047538-A1 | QUINOLIN-, ISOQUINOLIN-, AND QUINAZOLIN-OXYALKYLAMIDES AND THEIR USE AS FUNGICIDES | SYNGENTA LIMITED (GB) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072884-A1 | QUINOLIN-ISOQUINOLIN-AND QUINAZOLIN-OXYALKYLAMIDES AND THEIR USE AS FUNGICIDES | CBR3, CBR1, POR | HPGDS 4782/4885CDK5 3405/4885MAP4K4 3769/4885 |
| US-20060019973-A1 | Quinolin-,isoquinolin-,and quinazolin-oxyalkylamides and their use as fungicides | CYP4X1, CYP51A1, CYP1A2 | HPGDS 3951/4885CDK5 3901/4885MAP4K4 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.